The stock's near-term catalyst is the DAYBREAK Phase 3 readout in September 2026. Monitor cash runway closely, at the current burn rate, a dilutive equity offering is likely needed before mid-2027 to fund operations through the PEAK and PINNACLE readouts.
Drugs in focus
KOD drug pipeline →KSI-101
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
- Next catalyst
- None dated
What to watchThe December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.
Price Chart
Executive Summary
Kodiak Sciences reported Q2 2026 financial results with a net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, driven by increased R&D spending on late-stage trials. The pre-revenue biotech remains on track for three pivotal Phase 3 readouts by year-end: DAYBREAK (wet AMD) in September 2026 and PEAK (MESI) in December 2026. Cash burn accelerated to $84M in H1 2026, leaving $125.9M in cash, sufficient into 2027 but raising the likelihood of a dilutive financing before commercialization.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $65.6M ($1.05/share) vs $54.3M ($1.03/share) in Q2 2025.
- Cash and cash equivalents fell to $125.9M at June 30, 2026, from $209.9M at December 31, 2025.
- R&D expenses rose to $56.1M in Q2 2026 from $42.8M in Q2 2025, driven by PEAK/PINNACLE and manufacturing activities.
- Enrollment completed for the first 300-patient cohort of the Phase 3 PEAK study (KSI-101 in MESI); topline data expected December 2026.
- Phase 3 DAYBREAK study (Zenkuda and KSI-501 in wet AMD) topline data expected September 2026.
- First patients enrolled in the Phase 3 ALTO study of KSI-501 in diabetic macular edema (DME).
- BLA preparation activities for Zenkuda continue.
- Working capital decreased to $78.6M from $169.3M at year-end 2025.
- Total stockholders' equity fell to $61.1M from $157.4M at December 31, 2025.
Financial Impact
Net loss widened by $11.3M YoY to $65.6M in Q2 2026; cash burn of ~$84M in H1 2026
Risk Factors
- Cash burn rate is accelerating, with $84M consumed in H1 2026, potentially requiring dilutive financing before commercialization.
- Phase 3 DAYBREAK and PEAK readouts are binary events; failure to meet primary endpoints would significantly impair the pipeline's value.
- No revenue or approved products; the company is entirely dependent on clinical trial success and regulatory approvals.
- Accumulated deficit has grown to $1.68 billion, with no path to profitability in the near term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-349107 |
| Document: kod-20260813.htm | 0001193125-26-349107 |
| Document: 0001193125-26-349107-index-headers.html | 0001193125-26-349107 |
| Document: 0001193125-26-349107-index.html | 0001193125-26-349107 |
| Document: 0001193125-26-349107.txt | 0001193125-26-349107 |
| 8-K Data (Synthetic) | 0001193125-26-349107 |
Track record
13 reports on KOD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $100.73 +4.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $100.73 +8.01% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $100.73 −9.41% settles Dec 14
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $100.73 −5.95% settles Dec 8
- Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $100.73 −14.83% settles Nov 18
- Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
- Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $100.73 +12.02% ▼ −0.36% −0.32% vs SPY
- Aug 13, 202613w ago 8-K Neutral 4/10 Viewing No price data
- Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $100.73 +143.60% ▼ −19.85% −17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers